A detailed history of Meiji Yasuda Asset Management CO Ltd. transactions in Exact Sciences Corp stock. As of the latest transaction made, Meiji Yasuda Asset Management CO Ltd. holds 5,774 shares of EXAS stock, worth $286,043. This represents 0.02% of its overall portfolio holdings.

Number of Shares
5,774
Previous 5,774 -0.0%
Holding current value
$286,043
Previous $243,000 61.73%
% of portfolio
0.02%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$56.27 - $73.77 $35,450 - $46,475
630 Added 12.25%
5,774 $398,000
Q3 2023

Nov 13, 2023

BUY
$65.94 - $99.04 $9,891 - $14,856
150 Added 3.0%
5,144 $350,000
Q4 2022

Feb 14, 2023

BUY
$30.35 - $53.15 $151,567 - $265,431
4,994 New
4,994 $247,000
Q2 2022

Aug 16, 2022

BUY
$35.61 - $76.23 $8,190 - $17,532
230 Added 4.57%
5,264 $207,000
Q1 2022

May 17, 2022

SELL
$57.56 - $82.54 $57,905 - $83,035
-1,006 Reduced 16.66%
5,034 $352,000
Q4 2021

Feb 14, 2022

BUY
$72.5 - $100.68 $26,100 - $36,244
360 Added 6.34%
6,040 $470,000
Q2 2021

Aug 13, 2021

BUY
$93.66 - $139.27 $3,746 - $5,570
40 Added 0.71%
5,680 $706,000
Q1 2021

May 14, 2021

BUY
$116.57 - $155.01 $90,924 - $120,907
780 Added 16.05%
5,640 $743,000
Q4 2020

Feb 12, 2021

SELL
$99.61 - $142.12 $10,957 - $15,633
-110 Reduced 2.21%
4,860 $644,000
Q3 2020

Nov 12, 2020

SELL
$72.92 - $102.01 $72,920 - $102,010
-1,000 Reduced 16.75%
4,970 $507,000
Q2 2020

Aug 13, 2020

BUY
$55.75 - $92.75 $332,827 - $553,717
5,970 New
5,970 $519,000
Q3 2019

Nov 13, 2019

SELL
$90.37 - $122.49 $170,799 - $231,506
-1,890 Closed
0 $0
Q2 2019

Aug 13, 2019

BUY
$89.51 - $118.04 $169,173 - $223,095
1,890 New
1,890 $223,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $8.77B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Meiji Yasuda Asset Management CO Ltd. Portfolio

Follow Meiji Yasuda Asset Management CO Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Meiji Yasuda Asset Management CO Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Meiji Yasuda Asset Management CO Ltd. with notifications on news.